BeneFIX® was the first rFIX product licensed for patients with hemophilia B11 and it represents more than 20 years of commitment to innovation and improvement of outcomes for your patients.1,12*
Committed to the hemophilia B community for more than 20 years13,*
Complex Protein Production
Established cell line shown to be free of foreign agents and capable of producing large amounts of rFIX in an albumin-free medium.14,15
Customized purification processes designed with viral safety in mind.14,15
Over 150 quality control examinations are performed on each batch of BeneFIX® to help ensure a consistent purification process.16
The use of BeneFIX® in hemophilia B is supported by clinical trials and more than 20 years of clinical experience.10,13,17-20
AF-CC, albumin-free cell culture; EHL, Extended half-life; FIX, factor IX; FVIII, factor VIII; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PTPs, previously treated patients; PUPs, previously untreated patients; rFIX, recombinant factor IX.
BeneFIX® provides dosing options based on individual needs
Proven efficacy and protection across dosing regimen
Review efficacy profile
See how BeneFIX® performs in real-life settings.
Review real-world data
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022